Literature DB >> 20495790

Higher dopamine transporter density in Parkinson's disease patients with depression.

Andre C Felicio1, Tais S Moriyama, Clecio Godeiro-Junior, Ming C Shih, Marcelo Q Hoexter, Vanderci Borges, Sonia M A Silva, Edson Amaro-Junior, Luiz A F Andrade, Henrique B Ferraz, Rodrigo A Bressan.   

Abstract

RATIONALE: Depression is a frequent non-motor symptom in Parkinson's disease (PD) with increasing rates with the progression of the disease. Molecular imaging studies have shown a reduction of dopamine transporter (DAT) density in depressed PD patients (dPD); however, DAT role in the pathophysiology of PD depression is not clear since clinical matching was inappropriate and DAT reduction could be attributed to PD severity.
OBJECTIVES: To further examine the role of DAT in PD depression, this study compared thoroughly matched depressed vs. non-depressed PD patients (ndPD).
MATERIALS AND METHODS: Twenty PD patients (n = 10 ndPD; n = 10 dPD) matched for age and disease severity were submitted to brain SPECT imaging with [(99m)Tc]-TRODAT-1, a DAT radioligand. DAT-binding potential was calculated using regions of interest bilaterally drawn in the striatum, caudate, and putamen. Depression was defined according to Beck Depression Inventory (BDI; cut-off >18).
RESULTS: Mean BDI scores were higher in dPD (25.0 +/- 5.6) than in ndPD patients (8.0 +/- 1.9, p < 0.0001). DAT density was greater on dPD especially in the left caudate (dPD 0.87 +/- 0.19 vs. ndDP 0.69 +/- 0.18, p = 0.02) and right putamen (dPD 0.37 +/- 0.07 vs. ndPD 0.28 +/- 0.13, p = 0.03) than in ndPD patients.
CONCLUSION: Our results suggest that in vivo DAT density is increased in dPD patients as compared to ndPD, suggesting that DAT is implicated in the pathophysiology of PD depression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495790     DOI: 10.1007/s00213-010-1867-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.

Authors:  T Murai; U Müller; K Werheid; D Sorger; M Reuter; T Becker; D Y von Cramon; H Barthel
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

Review 2.  Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke.

Authors:  H Rickards
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Can molecular imaging techniques identify biomarkers for neuropsychiatric disorders?

Authors:  Rodrigo A Bressan; Ming C Shih; Marcelo Q Hoexter; Acioly L T Lacerda
Journal:  Braz J Psychiatry       Date:  2007-06       Impact factor: 2.697

4.  Lower dopamine transporter binding potential in striatum during depression.

Authors:  J H Meyer; S Krüger; A A Wilson; B K Christensen; V S Goulding; A Schaffer; C Minifie; S Houle; D Hussey; S H Kennedy
Journal:  Neuroreport       Date:  2001-12-21       Impact factor: 1.837

5.  The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.

Authors:  E Broussolle; C Dentresangle; P Landais; L Garcia-Larrea; P Pollak; B Croisile; O Hibert; F Bonnefoi; G Galy; J C Froment; D Comar
Journal:  J Neurol Sci       Date:  1999-07-01       Impact factor: 3.181

6.  Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Authors:  Daniel Weintraub; Andrew B Newberg; Mark S Cary; Andrew D Siderowf; Paul J Moberg; Galit Kleiner-Fisman; John E Duda; Matthew B Stern; David Mozley; Ira R Katz
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging.

Authors:  David J Brunswick; Jay D Amsterdam; P David Mozley; Andrew Newberg
Journal:  Am J Psychiatry       Date:  2003-10       Impact factor: 18.112

8.  Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.

Authors:  Irena Rektorova; Hana Srovnalova; Radka Kubikova; Jiri Prasek
Journal:  Mov Disord       Date:  2008-08-15       Impact factor: 10.338

9.  Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease.

Authors:  Janneke Koerts; Klaus L Leenders; Marthe Koning; Axel T Portman; Marije van Beilen
Journal:  Eur J Neurosci       Date:  2007-05       Impact factor: 3.386

10.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

Authors:  Philippe Remy; Miroslava Doder; Andrew Lees; Nora Turjanski; David Brooks
Journal:  Brain       Date:  2005-02-16       Impact factor: 13.501

View more
  20 in total

Review 1.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 2.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

3.  Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [(99m)Tc]TRODAT-1.

Authors:  Marcelo Q Hoexter; Gustavo Fadel; André C Felício; Mariana B Calzavara; Ilza R Batista; Marilia A Reis; Ming C Shih; Roger K Pitman; Sérgio B Andreoli; Marcelo F Mello; Jair J Mari; Rodrigo A Bressan
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

4.  Reversible abnormal functional neuroimaging presentations in polycythemia vera with chorea.

Authors:  Hui-Chun Huang; Yu-Chin Wu; Lee-Yung Shih; Woei-Chung Lo; Chon-Haw Tsai; Woei-Cherng Shyu
Journal:  J Neurol       Date:  2011-05-11       Impact factor: 4.849

Review 5.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

Review 6.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

7.  Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment.

Authors:  Ying Liu; Mei Han; Xingdang Liu; Yanping Deng; Yu Li; Jie Yuan; Rongbin Lv; Yuankai Wang; Guangming Zhang; Jinlong Gao
Journal:  Psychopharmacology (Berl)       Date:  2013-05-29       Impact factor: 4.530

Review 8.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

9.  Affective disorders in Parkinson's disease.

Authors:  Kelly S G Aminian; Antonio P Strafella
Journal:  Curr Opin Neurol       Date:  2013-08       Impact factor: 5.710

Review 10.  Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders.

Authors:  Elizabeth K Nousen; Juliana G Franco; Elinor L Sullivan
Journal:  Neuroendocrinology       Date:  2013-09-21       Impact factor: 4.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.